Dublin, June 21, 2022 (GLOBE NEWSWIRE) — The “Global Breast Cancer Monoclonal Antibody Market Report 2022: By Product, By End User” report has been added to from ResearchAndMarkets.com offer.
The global breast cancer monoclonal antibody market is expected to grow from USD 15.37 billion in 2021 to USD 16.67 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The market is expected to reach $21.47 billion in 2026 with a CAGR of 6.5%.
Major players in the breast cancer monoclonal antibody (mAb) market include Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.
The Breast Cancer Monoclonal Antibodies (mAbs) market includes sales of monoclonal antibodies by entities (organizations, individual traders, and partnerships) that produce breast cancer monoclonal antibodies used as a treatment for breast cancer as monotherapy or in combination. combination therapy. Revenues generated include sales of bare mAbs and conjugated mAbs.
The companies active in the breast cancer monoclonal antibody market mainly focus on the research, development and production of monoclonal antibodies used in early stage and late stage breast cancer, ductal carcinoma in situ, triple negative breast cancer, inflammatory breast cancer. cancer, and others.
The main types of breast cancer monoclonal antibodies are naked mAbs and conjugated mAbs. Naked mAbs are antibodies that are free of any drugs or radioactive materials. They are autonomous. The most common type of mAb used to fight cancer is this one. The different types of treatments include chemotherapy, surgery and radiotherapy, targeted therapy, biological therapy, hormone therapy and are used in various sectors such as hospitals, retail pharmacies.
Alternative treatment methods and natural remedies are becoming increasingly popular globally, which is expected to impact the revenue of breast cancer monoclonal antibody manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and are slowly replacing some traditional hospital practices.
For example, Ayurvedic medicine, an ancient Indian system of medicine, uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anticancer properties. According to the World Health Organization (WHO), some countries are still reacting to herbal treatment as the main source of medicines, and developing countries are using the benefits of natural compounds for therapeutic purposes, which affects medicine sales. oncology. Furthermore, the global homeopathic products market is expected to reach $18.6 billion by the end of 2027.
The National Cancer Institute reported promising results from vaccines against HER2-positive cancer, including breast, ovarian, lung, colorectal, and gastroesophageal cancers, in which they used the immune cells of patients to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccine. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibody market.
Companies in the breast cancer monoclonal antibody market are investing in targeted and combination therapy, which has been shown to be more effective and less toxic than traditional treatment options. Targeted cancer therapies are drugs or substances that block cancer growth by interfering with molecules that are more specifically involved in cancer cell progression than normal cell activity.
The goal of these therapies is to eliminate cancerous cells from the body while leaving normal cells unharmed. By focusing on cancer-specific cellular changes, this therapy may prove more effective than traditional chemotherapy and radiation therapy. Combination therapy uses a method of treatment in which a patient receives two or more drugs (or other therapeutic agents) for a single disease.
In February 2019, the FDA approved the combination of an mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer in which hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, the American Society of Clinical Oncology published the successful combination therapy of a targeted monoclonal antibody, atezolizumab, with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer .
This resulted in a progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received the placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to draw attention to these therapies in the breast cancer monoclonal antibody market.
Main topics covered:
2. Characteristics of the Breast Cancer Monoclonal Antibody Market
3. Breast Cancer Monoclonal Antibody Market Trends and Strategies
4. Impact of COVID-19 on breast cancer monoclonal antibodies
5. Breast Cancer Monoclonal Antibody Market Size and Growth
5.1. Global Breast Cancer Monoclonal Antibody Historic Market, 2016-2021, in USD Billion
5.1.1. Market Drivers
5.1.2. Market Constraints
5.2. Global Breast Cancer Monoclonal Antibody Market Forecast, 2021-2026F, 2031F, USD Billion
5.2.1. Market Drivers
5.2.2. Market Constraints
6. Breast Cancer Monoclonal Antibody Market Segmentation
6.1. Global Breast Cancer Monoclonal Antibody Market, Segmentation by Product, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD
- Naked mabs
- Conjugated Mabs
6.2. Global Breast Cancer Monoclonal Antibody Market, Segmentation by End-User, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD
- Retail pharmacies
6.3. Global Breast Cancer Monoclonal Antibody Market, Segmentation by Treatment, History & Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD
- Surgery and radiotherapy
- Targeted therapy
- biological therapy
- Hormone therapy
7. Regional and Country Analysis of the Breast Cancer Monoclonal Antibody Market
7.1. Global Breast Cancer Monoclonal Antibody Market, Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2. Global Breast Cancer Monoclonal Antibody Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
- Daiichi Sankyo
- Boehringer Ingelheim
- Bristol Myers Squibb
- Table BioPharma
- Celldex therapeutics
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals
- Puma Biotechnology
- Seattle Genetics
- Astra Zeneca
- Galena Biopharma
For more information on this report, visit https://www.researchandmarkets.com/r/jr4189